Clinical Trials Logo

Clinical Trial Summary

This is an investigator-initiated, one-armed, phase 2 clinical trial using an injectable fluorescent tracer to assay and evaluate measured plasma volume (mPV) and measured glomerular filtration rate (mGFR) in hospitalized patients with acute decompensated congestive heart failure (CHF).


Clinical Trial Description

This investigator-initiated, one-armed study is designed to evaluate the safety and function of the FAST PV and mGFR Technology in patients with CHF. Data from the FAST PV and mGFR Technology will not be evaluable by the treating physician, but will be made available to the study investigators and to an adjudication committee. Patients enrolled in the study will be administered the VFI (Day 1) and with a second dose occurring 24-48 hours after the initial dose (Day 3). After consenting to be enrolled in the study, patients meeting the enrollment criteria will receive a single dose of two component VFI. Blood draws (3 mL) will be collected pre-dose and at 15, 30, 60, and 180 minutes post-dose, which will be subsequently used to determine the patient's blood volume and mGFR using the FAST PV and mGFR Technology. Patients will be treated according to standard of care throughout the time of their hospitalization. A second dose of VFI will be administered 48 (+/- 5) hours after the initial dosing. Again, blood draws (3 mL) will be collected pre-dose and at 15, 30, 60, and 180 minutes post-dose. Plasma volume (PV) was determined using the average concentrations of the higher molecular marker of VFI of the early 15 min and the 60 min time point. The concentration of the small dextran GFR marker at time zero was back calculated from the measured PV by dividing the known dose into the measured PV. The time points were then fitted using atwo-compartment model and the resulting area under the curve was calculated. The use of the time point 0 determination helped to better resolve the shape of the clearance curve. Study-related blood samples will be obtained on days 1, 2, 3, 4, and 5 to measure serum creatinine (days 1-5), hematocrit (days 1, 3), and N-terminal pro-brain natriuretic peptide (NT-pro-BNP), creatine phosphokinase (CPK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, bilirubin total and direct, and international normalized ratio (INR) (days 1, 3, and 5); and will be stored for future testing of additional parameters in the research fields of acute decompensated heart failure and acute kidney injury. The available laboratory values will be entered in the Dosing Day Case Report Form (CRF), along with any copies of physician's notes and orders entered that day. Prior to administering the first and second dose of VFI, the physician will be asked to complete a very brief survey to provide a qualitative assessment of the patient's perceived volume status and renal function prior to initiating the FAST PV and mGFR measurements. Laboratory values and assessments will be captured on each day that the VFI is administered, and these data will be entered into the CRF. Any adverse events (AEs) determined by the investigator to be related or possibly related to the VFI will be captured. Patients will receive a followup phone call 7 days (± 2 days) after the first dose of VFI was administered, and a second follow up call 30 days after the first dose of VFI was administered as an end of study (EOS) follow up call. Any AEs determined by the investigator will be captured during the follow up calls and will be followed to resolution. Additionally, in-person follow-up visits may be scheduled as needed. Upon conclusion of the study, the recorded clinical data will be provided to an independent data adjudication committee (DAC) in a pseudonymized fashion. The DAC will be asked to review the available data at the time of the first dosing, and the measured GFR and PV data for the first dosing day will be provided. The DAC will then be asked to fill out a survey asking whether the mGFR and PV data would have influenced their treatment decision, and if so, indicate what they would have done differently. Following the evaluation of mGFR and PV data at the time of the initial VFI dose, the mGFR and PV data determined from the second VFI dosing point will be provided to the DAC. The DAC will then be asked to fill out a separate survey asking how the actual measured PV and GFR differ from the clinical assessments, whether the mGFR and PV data would influence their treatment decision, and if so, indicate what they would have done differently. After all assessments have been completed, the DAC will review the results of their analyses and compile a summary report on the secondary endpoints as well as their assessment of the overall impact of the PV and mGFR on clinical decision making. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03808948
Study type Interventional
Source Charite University, Berlin, Germany
Contact
Status Completed
Phase N/A
Start date January 10, 2019
Completion date August 17, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT03463148 - Validation of a Sensor for Non-Invasive Measurements
Completed NCT03339310 - Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System N/A
Completed NCT00288587 - Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF) Phase 4
Recruiting NCT05423652 - Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound N/A
Recruiting NCT05865197 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF
Recruiting NCT02020811 - Safety and Efficacy of Immages System in Patients Recieving IV Therapy N/A
Withdrawn NCT01809730 - Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients N/A
Completed NCT01316432 - PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients Phase 1
Completed NCT02632552 - A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD N/A
Completed NCT03207802 - Remotely Monitoring Patients With Chronic Conditions in Their Home
Terminated NCT04154579 - Arts & Health Education to Improve Health, Resilience, and Well-Being N/A
Terminated NCT03102437 - Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System N/A
Recruiting NCT04591964 - Effects of Remote Monitoring of Patients With Heart Failure Based on Smartphone Application Early Phase 1
Completed NCT05843201 - AquaPass Device in Treatment of CHF Patients N/A
Active, not recruiting NCT04090671 - Evaluation of the Multidimensional Dyspnea Profile (MDP) N/A
Recruiting NCT03905252 - Biomarkers for Human Heart Failure
Completed NCT04261452 - Heart Failure Worsens Muscle Strength in COPD N/A
Not yet recruiting NCT02873000 - Incentive Spirometry in Non-critically Ill Hospitalized Patients With Acute Respiratory Failure N/A